Treatments 

 Nitisinone

 

The drug nitisinone is thought to be the first treatment for alkaptonuria (AKU). Previous research has shown that nitisinone can reduce the levels of homogentisic acid (HGA) by up to 95 %. Animal models have shown that, if administered early enough, nitisinone could potentially prevent the disease from developing. 

The US National Institutes of Health (NIH) began a three-year clinical trial of nitisinone in April 2005. Unfortunately, the results were inconclusive, and more work needs to be done before the drug can be approved as a treatment for AKU. 

We were involved in a series of clinical trials called DevelopAKUre, lasting five-and-a-half years. The trials followed AKU patients taking nitisinone to see if the drug has any effect on the disease. The trials showed that nitisinone has a positive effect on treating AKU. Due to this, SOBI (Swedish Orphan Biovitrum) are applying to the European Medicines Agency (EMA) for marketing authorisation for the drug. If successful, this could lead to nitisinone becoming a licenced drug for treating AKU.  Further information can also be found on our clinical trials website, www.developakure.eu. 

As nitisinone is licensed for another rare disease, hereditary tyrosinemia type 1 or HT1, doctors can prescribe it to AKU patients off-label. Off-label means prescribing a drug for a condition that the drug wasn’t initially intended for. Nitisinone is currently prescribed off-label to English and Scottish patients who attend the National AKU Centre (NAC) in Liverpool. Patients in Wales and Northern Ireland do not currently have funding for nitisinone. 
To find out more about the NAC, contact Lesley Harrison, our Patient Support Manager, by emailing her at lesley@akusociety.org.


Joint replacements

AKU causes extreme wear and tear on the joints, so many patients have joint replacements. This helps to relieve pain and increases mobility. It is important to speak to your doctor and be referred to a specialist if you need a joint replacement. Most of our patients have at least one joint replacement in their lifetime, often much more. If you are going for a joint replacement in the UK, find out more about the National Joint Registry (NJR). The NJR collects information on joint replacement surgery and monitors the performance of artificial joints. Your surgeon or specialist should tell you more about the NJR before your joint replacement.

If you are an AKU patient in the UK who has a joint replacement operation planned, and would like to discuss donating a sample to benefit AKU research, please contact Lesley Harrison at lesley@akusociety.org who can provide further information.

 

Published: 24.07.16 Next Review Date: 24.07.19





AKU Twitter

AKU Blog

DevelopAKUre - A History
02-Aug-2019

Today's blog is written by Nick Sireau the Chair and CEO of the AKU Society, It was in.. ...more

SONIA 2 and DevelopAKUre - Results
23-Jul-2019

We are delighted to announce that all the data from the SONIA 2 clin.. ...more

Sociological Study on Treatment for AKU in the UK
19-Jul-2019

My name is Alev Sen. I’m the main researcher on a study of treatment for AKU in UK hea.. ...more

Other Ways to Give to the AKU Society
04-Jul-2019

In this week’s blog, we explain how you can donate to the AKU Society through mobile g.. ...more

Stand Up To AKU Comedy Night - Liverpool 2019
20-Jun-2019

Our ‘Stand Up to AKU’ comedy night was on Sunday the 9th of June at the Hot Wate.. ...more